SEARCH

SEARCH BY CITATION

References

  • 1
    Crawford RW, Murray DW. Total hip replacement: indications for surgery and risk factors for failure. Ann Rheum Dis 1997; 56: 455457.
  • 2
    National Total Hip Replacement Outcome Study: Final Report to the Department of Health – The Royal College of Surgeons of England. [online] 2000 Available at www.rcseng.ac.uk/publications/docs/hip_replacement.html (accessed 18 April 2011).
  • 3
    Dreinhöfer KE, Dieppe P, Stürmer T et al. Indications for total hip replacement: comparison of assessments of orthopaedic surgeons and referring physicians. Ann Rheum Dis 2006; 65: 13461350.
  • 4
    Achten J, Parsons NR, Edlin RP, Griffin DR, Costa ML. A randomised controlled trial of total hip arthroplasty versus resurfacing arthroplasty in the treatment of young patients with arthritis of the hip joint. BMC Musculoskelet Disord 2010; 11: 8.
  • 5
    Marker DR, Strimbu K, McGrath MS, Zywiel MG, Mont MA. Resurfacing versus conventional total hip arthroplasty – review of comparative clinical and basic science studies. Bull NYU Hosp Jt Dis 2009; 67: 120127.
  • 6
    Snir N, Wolfson TS, Schwarzkopf R et al. Outcomes of total hip arthroplasty in human immunodeficiency virus-positive patients. J Arthroplasty 2014; 29: 157161.
  • 7
    Capogna BM, Lovy A, Blum Y, Kim SJ, Felsen UR, Geller DS. Infection rate following total joint arthroplasty in the HIV population. J Arthroplasty 2013; 28: 12541258.
  • 8
    Tornero E, Garcia S, Larrousse M et al. Total hip arthroplasty in HIV-infected patients: a retrospective, controlled study. HIV Med 2012; 13: 623629.
  • 9
    Mahoney CR, Glesby MJ, DiCarlo EF, Peterson MG, Bostrom MP. Total hip arthroplasty in patients with human immunodeficiency virus infection: pathologic findings and surgical outcomes. Acta Orthop 2005; 76: 198203.
  • 10
    Lubega N, Mkandawire NC, Sibande GC, Norrish AR, Harrison WJ. Joint replacement in Malawi: establishment of a National Joint Registry. J Bone Jt Surg Br 2009; 91: 341343.
  • 11
    Goorney BP, Lacey H, Thurairajasingam S, Brown JD. Avascular necrosis of the hip in a man with HIV infection. Genitourin Med 1990; 66: 451452.
  • 12
    Miller KD, Masur H, Jones EC et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002; 137: 1725.
  • 13
    Brown P, Crane L. Avascular necrosis of bone in patients with human immunodeficiency virus infection: report of 6 cases and review of the literature. Clin Infect Dis 2001; 32: 12211226.
  • 14
    Lawson-Ayayi S, Bonnet F, Bernardin E et al. Avascular necrosis in HIV-infected patients: a case-control study from the Aquitaine Cohort, 1998–2002, France. Clin Infect Dis 2005; 40: 11881193.
  • 15
    Lavernia CJ, Sierra RJ, Grieco FR. Osteonecrosis of the femoral head. J Am Acad Orthop Surg 1999; 7: 250261.
  • 16
    Steinberg ME, Hayken GD, Steinberg DR. A quantitative system for staging avascular necrosis. J Bone Jt Surg 1995; 77B: 3441.
  • 17
    Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Jt Surg Am 2005; 87: 21552159.
  • 18
    Agarwala S, Shah S, Joshi VR. The use of alendronate in the treatment of avascular necrosis of the femoral head: follow up to eight years. J Bone Joint Surg Br 2009; 91: 10131018.
  • 19
    Chen C, Chang J, Lai K, Hou S, Chang C, Wang G. Alendronate in the prevention of collapse of the femoral head in nontraumatic osteonecrosis: a two-year multicentre, prospective, randomised, double-blind, placebo-controlled study. Arth Rheum 2012; 64: 15721578.
  • 20
    Pivec R, Johnson AJ, Harwin SF, Mont MA. Differentiation, diagnosis, and treatment of osteoarthritis, osteonecrosis, and rapidly progressive osteoarthritis. Orthopedics 2013; 36: 118125.
  • 21
    Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41 (RR-17): 119.
  • 22
    Niven DJ, Berthiaume LR, Fick GH, Laupland KB. Matched case-control studies: a review of reported statistical methodology. Clin Epidemiol 2012; 4: 99110.
  • 23
    De Larranaga G, Bottaro E, Martinuzzo M et al. Thrombophilia in human immunodeficiency virus-infected patients with osteonecrosis: is there a real connection? The first case-control study. Clin Appl Thromb Hemost 2009; 15: 340347.
  • 24
    Mazzotta E, Agostine A, Rosso R et al. Osteonecrosis in human immunodeficiency (HIV)-infected patients: a multicentric case-control study. J Bone Miner Metab 2011; 29: 383388.
  • 25
    Chen F, Kearney T, Robinson S, Daley-Yates PT, Waldron S, Churchill DR. Cushing syndrome and severe adrenal suppression in patients treated with Ritonavir and inhaled nasal fluticasone. Sex Transm Infect 1999; 75: 274.
  • 26
    Danaher PJ, Salsbury TL, Delmar JA. Metabolic derangement after injection of Triamcinolone into the hip of an HIV-infected patient receiving ritonavir. Orthopedics 2009; 32: 450.